Aliskiren
6,420 views
Cardiovascular Pharm (Old)
- Adenosine
- Magnesium
- Nitroprusside
- Nitrates
- Ivabradine
- Digoxin/Digitalis
- Class IA Antiarrhythmics
- Class IB Antiarrhythmics
- Class IC Antiarrhythmics
- Class II Antiarrhythmics
- Class III Antiarrhythmics - Amiodarone
- Class III Antiarrythmics - Sotalol
- Class III Antiarrhythmics - Ibutilide, Dofetilide
- Class IV Antiarrhythmics - Verapamil, Diltiazem
- HMG-CoA Reductase Inhibitors (Statins)
- Ezetimibe
- Fibrates
- PCSK9 Inhibitors (Alirocumab, Evolocumab)
- Fish Oil and Omega-3s
- Milrinone
- Aliskiren
- Hydralazine
- Ranolazine
- Sacubitril
Summary
Aliskiren is a direct renin inhibitor primarily used in the treatment of hypertension. Importantly, aliskiren is a teratogen, and should be avoided in pregnant women.
Key Points
- Aliskiren
- MOA
- Direct renin inhibitor
- preventing renin-mediated conversion of angiotensinogen to angiotensin I
- Direct renin inhibitor
- Indications
- Hypertension
- Can be combined with other antihypertensive agents such as amlodipine or hctz
- Hypertension
- Side Effects
- Teratogen
- Contraindicated in pregnancy
- Effects of renin inhibition
- Hyperkalemia
- Decreased GFR
- Angioedema
- Relatively contraindicated in patients already taking ACEI or ARBs; synergistic effects may induce hypotension
- Non-specific: diarrhea, cough, nausea
- Teratogen
- MOA